project id: TCGA-PRAD; case submitter id: TCGA-KC-A7FE; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.82; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.31; rna integrity number: 8.3; age at index: 62; days to birth: -22718; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1951; age at diagnosis: 22718; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 352.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 212; initial weight: 120.0; sample id: 4c49cc14-5813-4a6a-bb8e-4cddef2d5055; sample submitter id: TCGA-KC-A7FE-01A; portion id: beb2cce6-c0ad-48b7-9f83-64d9471b0cfa; portion submitter id: TCGA-KC-A7FE-01A-01; slide id: 7333a063-1621-4757-989f-8abcfcb2c4db; slide submitter id: TCGA-KC-A7FE-01A-01-TSA; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 40.0; percent tumor cells: 60.0; percent tumor nuclei: 60.0; section location: TOP;